WIPOSchützen Sie diese Marke vor Nachahmern!
Mit unserer Markenüberwachung werden Sie automatisch per E-Mail über Nachahmer und Trittbrettfahrer benachrichtigt.
Die Internationale Marke MYOGENDYS wurde als Wortmarke am 15.10.2020 bei der Weltorganisation für geistiges Eigentum angemeldet.
| Markenform | Wortmarke |
| Aktenzeichen | 1585602 |
| Länder | 
|
| Basismarke |
Nr. 88886717,
24. April 2020
|
| Anmeldedatum | 15. Oktober 2020 |
| Ablaufdatum | 15. Oktober 2030 |
Markeninhaber
215 First Street
Cambridge MA 02142
US
Cambridge MA 02142
US
Markenvertreter
3724 Benson Drive
Raleigh NC 27609
US
Waren und Dienstleistungen
05
Pharmaceutical preparations for the treatment of
neuromuscular diseases and disorders, muscular dystrophies,
central nervous system diseases and disorders, genetic
diseases and disorders; pharmaceutical preparations based on
morpholino oligomer technology platform for the treatment of
neuromuscular diseases and disorders, muscular dystrophies,
central nervous system diseases and disorders, genetic
diseases and disorders, and for the regulation of protein
production; pharmaceutical preparations that modulate rna
expression for the treatment of neuromuscular diseases and
disorders, muscular dystrophies, central nervous system
diseases and disorders, genetic diseases and disorders, and
for the regulation of protein production; gene therapy
products, namely, gene delivery pharmaceuticals;
pharmaceutical preparations for gene therapy, gene editing,
and genome editing; gene therapy products for the treatment
of neuromuscular diseases and disorders, muscular
dystrophies, central nervous system diseases and disorders,
genetic diseases and disorders; biological preparations for
the treatment of neuromuscular diseases and disorders,
muscular dystrophies, central nervous system diseases and
disorders, genetic diseases and disorders; viruses, viral
vectors and viral constructs, all of the foregoing used as
delivery agents, for the treatment of neuromuscular diseases
and disorders, muscular dystrophies, central nervous system
diseases and disorders, genetic diseases and disorders;
pharmaceutical preparations, biological preparations and
gene therapy products in the nature of pharmaceutical and
biological preparations for the treatment of genetic
disorders and diseases
Die Bezeichnungen wurden automatisch übersetzt. Übersetzung anzeigen
Markenhistorie
| Datum | Belegnummer | Bereich | Eintrag |
|---|---|---|---|
| 10. November 2022 | 2022/48 Gaz | US | RAW: Total Ceasing Effect |
| 13. Oktober 2022 | 2022/41 Gaz | KR | Ablehnung |
| 21. September 2022 | 2022/40 Gaz | IS | Ablehnung |
| 05. August 2022 | 2022/32 Gaz | CA | Ablehnung |
| 07. Juli 2022 | 2022/27 Gaz | MX | Ablehnung |
| 10. Mai 2022 | 2022/19 Gaz | KR | Ablehnung |
| 09. März 2022 | 2022/10 Gaz | CH | Ablehnung |
| 03. März 2022 | 2022/9 Gaz | NO | Ablehnung |
| 28. Februar 2022 | 2022/9 Gaz | TR | Ablehnung |
| 10. Februar 2022 | 2022/6 Gaz | JP | Ablehnung |
| 16. November 2021 | 2021/46 Gaz | BR | Ablehnung |
| 11. Oktober 2021 | 2021/41 Gaz | IN | Ablehnung |
| 18. August 2021 | 2021/33 Gaz | GB | Ablehnung |
| 06. August 2021 | 2021/32 Gaz | CN | Ablehnung |
| 28. Juni 2021 | 2021/26 Gaz | RU | Ablehnung |
| 15. Oktober 2020 | 2021/12 Gaz | US | Eintragung |
ID: 141585602